LEADER 04449nam 22006134a 450 001 9910144101203321 005 20170815115639.0 010 $a1-281-93752-5 010 $a9786611937522 010 $a0-470-37253-2 010 $a0-470-37252-4 035 $a(CKB)1000000000553427 035 $a(EBL)362146 035 $a(OCoLC)437224724 035 $a(SSID)ssj0000141611 035 $a(PQKBManifestationID)11148636 035 $a(PQKBTitleCode)TC0000141611 035 $a(PQKBWorkID)10079799 035 $a(PQKB)10067812 035 $a(MiAaPQ)EBC362146 035 $a(EXLCZ)991000000000553427 100 $a20080122d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug-induced mitochondrial dysfunction$b[electronic resource] /$fedited by James A. Dykens, Yvonne Will 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2008 215 $a1 online resource (648 p.) 300 $aDescription based upon print version of record. 311 $a0-470-11131-3 320 $aIncludes bibliographical references and index. 327 $aDRUG-INDUCED MITOCHONDRIAL DYSFUNCTION; CONTENTS; CONTRIBUTORS; PREFACE; PART I BASIC CONCEPTS; 1 Basic Mitochondrial Physiology in Cell Viability and Death; 2 Basic Molecular Biology of Mitochondrial Replication; 3 Drug-Associated Mitochondrial Toxicity; 4 Pharmacogenetics of Mitochondrial Drug Toxicity; PART II ORGAN DRUG TOXICITY: MITOCHONDRIAL ETIOLOGY; 5 Features and Mechanisms of Drug-Induced Liver Injury; 6 Cardiovascular Toxicity of Mitochondrial Origin; 7 Skeletal Muscle and Mitochondrial Toxicity; 8 Manifestations of Drug Toxicity on Mitochondria in the Nervous System 327 $a9 Lipoatrophy and Other Manifestations of Antiretroviral Therapeutics10 Nephrotoxicity; 11 Drug Effects in Patients with Mitochondrial Diseases; PART III ASSESSMENT OF MITOCHONDRIAL FUNCTION IN VITRO AND IN VIVO; 12 Polarographic Oxygen Sensors, the Oxygraph, and High-Resolution Respirometry to Assess Mitochondrial Function; 13 Use of Oxygen-Sensitive Fluorescent Probes for the Assessment of Mitochondrial Function; 14 Mitochondrial Dysfunction Assessed Quantitatively in Real Time by Measuring the Extracellular Flux of Oxygen and Protons 327 $a15 Assessment of Mitochondrial Respiratory Complex Function In Vitro and In Vivo16 OXPHOS Complex Activity Assays and Dipstick Immunoassays for Assessment of OXPHOS Protein Levels; 17 Use of Fluorescent Reporters to Measure Mitochondrial Membrane Potential and the Mitochondrial Permeability Transition; 18 Compartmentation of Redox Signaling and Control: Discrimination of Oxidative Stress in Mitochondria, Cytoplasm, Nuclei, and Endoplasmic Reticulum; 19 Assessing Mitochondrial Protein Synthesis in Drug Toxicity Screening 327 $a20 Mitochondrial Toxicity of Antiviral Drugs: A Challenge to Accurate Diagnosis21 Clinical Assessment of Mitochondrial Function via [(13)C]Methionine Exhalation; 22 Assessment of Mitochondrial Dysfunction by Microscopy; 23 Development of Animal Models of Drug-Induced Mitochondrial Toxicity; 24 Noninvasive Assessment of Mitochondrial Function Using Nuclear Magnetic Resonance Spectroscopy; 25 Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations; INDEX 330 $aThis is the definitive, one-stop resource on preclinical drug evaluation for potential mitochondrial toxicity, addressing the issue upfront in the drug development process. It discusses mitochondrial impairment to organs, skeletal muscle, and nervous systems and details methodologies used to assess mitochondria function. It covers both in vitro and in vivo methods for analysis and includes the latest models. This is the authoritative reference on drug-induced mitochondrial dysfunction for safety assessment professionals in the pharmaceutical industry and for pharmacologists and toxicologists i 606 $aDrugs$xToxicology 606 $aMitochondrial pathology 608 $aElectronic books. 615 0$aDrugs$xToxicology. 615 0$aMitochondrial pathology. 676 $a615.9 676 $a615/.1 701 $aDykens$b James Alan$f1951-$0924227 701 $aWill$b Yvonne$0924228 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144101203321 996 $aDrug-induced mitochondrial dysfunction$92074090 997 $aUNINA